Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


A New Idea To Solve The Turing Problem – If Anyone Notices

Executive Summary

The Fair Pricing Coalition previewed its upcoming ‘first hundred days’ proposal for drug pricing reforms – one of many Washington policy documents that was prepared with a very different election result in mind. But one new idea in the report deserves serious attention because it would actually directly address the ‘repricing’ strategy that drove the headlines over the past year.

You may also be interested in...

US Pharma Faces First Drug Pricing Fight Of 2021

A $16bn provision to increase rebates in the US Medicaid program is a surprise inclusion in the COVID relief package moving through Congress. It looks like an uphill fight for industry to stop it from happening.

Drug Affordability Review By National Academies Kicks Off With Lower Profile Than Expected

A National Academies of Sciences, Engineering and Medicine project on drug access and affordability is kicking off with a very different political backdrop for its deliberations than the one that seemed likely when the working group was selected in late October; its work may still end up mattering a great deal, if and when innovator pricing is back on the table for serious policy review.

The Trump Rally: GOP Sweep Is Good News For Biopharma – But Don’t Get Carried Away

Wall Street has made up its mind that the Nov. 8 US elections were great for biopharma companies. But is it really that clear cut?

Related Content


Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts